Clinical trials for Liver and bile duct cancer

153 currently recruiting clinical trials
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Cohortes C, D
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte F
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Sarcoma and GIST Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic types
Stomach Oesogastric junction Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma Ampullary carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1) CPS Positive (1 <= X < 5)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
7 recruiting sites
UNICANCER
Phase 2 Pancreas cancer Liver and bile duct cancer #NCT07478523 #2024-517270-23-00
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
CHU de Bordeaux
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Bayer
Phase 2 Liver and bile duct cancer #NCT06254248 #2024-514400-14-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Transplant
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 2 Liver and bile duct cancer #NCT07122089
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Localized Locally Advanced
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
2 recruiting sites
Centre Eugène Marquis
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
EGFR FGFR MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2 Liver and bile duct cancer #NCT07036380 #2024-520029-35-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
9 recruiting sites
Centre Hospitalier Universitaire de Besancon